Posted on

CareDx Extends Artificial Intelligence Leadership to Heart Transplantation

Loading

New Addition to CareDx HeartCare Multimodality Portfolio Can Enable More Precise, Personalized Patient Care

SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that through its ongoing partnership with OrganX, a non-profit health organization focused on cutting-edge digital health solutions, it plans to expand its HeartCare multimodality portfolio with a new artificial intelligence (AI) prognostic for cardiac allograft vasculopathy (CAV).
Read the complete press release on CareDx.com.

Loading
Posted on

CareDx CEO and President, Reg Seeto, Joins ISHLT Foundation Global Steering Committee Focused on Driving Innovations for Heart and Lung Transplant Patients

Loading

SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced Reg Seeto’s selection by the newly formed International Society for Heart and Lung Transplantation (ISHLT) Foundation to serve as Corporate Chair of the organization’s Global Steering Committee. Reg Seeto, MB.BS, will join Fundraising Chair Frank Pagani, MD and Foundation Chair James Kirklin, MD to help drive a multiyear campaign, the “Fostering Excellence Campaign,” which is focused on vitally important research to improve outcomes for patients with advanced heart and lung disease and organ transplants.

Read the full press release on CareDx.com here.

Loading
Posted on

CareDx Demonstrates Potential of AlloHeme and AlloCell for Allogeneic Cell Transplant and Therapy Monitoring at Transplantation & Cellular Therapy Meetings

Loading

CareDx Announces that OTTR Patient Management Software Now Validated for SMART on FHIR

SOUTH SAN FRANCISCO, Calif., April 22, 2022 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the presentation of new data during the Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR being held on April 23-26 in Salt Lake City, Utah, highlighting the capabilities of AlloHeme™ and AlloCell for allogeneic cell transplant and therapy monitoring.  
Read the full press release on CareDx.com here.

Loading
Posted on

CareDx Supports UC Davis Health Pluralist Program Aimed at Reducing Health Disparities in Organ Transplantation

Loading

SOUTH SAN FRANCISCO, Calif., April 21, 2022 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that as part of its investment in health equity improvements, it is contributing to a new program led by UC Davis Health that aims to improve knowledge about and access to organ donation and transplantation in underserved communities throughout California. Read the complete press release here.

Loading
Posted on

CareDx Reports Over 200,000 Heart Transplant Patient Results Served

Loading

CareDx Testing Services Have Been Used in Over 30,000 Heart Transplant Patients and Over 90 Percent of Centers in the United States

SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it has delivered over 200,000 AlloMap® or AlloSure® results for over 30,000 heart transplant recipients.1

“We are proud to have a long-standing and trusted relationship with the heart transplant community. Since 2005, we have served half of all heart transplant patients in the U.S. with AlloMap or AlloSure, and AlloMap has the distinction of being the only FDA cleared gene-expression profiling test (GEP) for use in heart transplants, the only GEP incorporated in International Society for Heart and Lung Transplantation guidelines, and the only one covered by CMS for multimodality assessment using AlloSure donor-derived cell-free DNA,” said Reg Seeto, CEO and President of CareDx. “Importantly, we have earned this trust by conducting multi-center prospective studies that have been published in leading journals such as the New England Journal of Medicine.”
Read the complete press release on CareDx.com here.

Loading
Posted on

CareDx, the Leading Sponsor of UNOS Transplant Management Forum, Demonstrates the Value of Digital Solutions to Improve Pre-Transplant Patient Referral and Waitlisting Workflow

Loading

CareDx’s TxAccess Digital Platform Helps Move Pre-Transplant Patients to Transplant Faster

SOUTH SAN FRANCISCO, Calif., April 11, 2022 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will host a lunch and learn session offering strategies and digital solutions to help transplant centers thrive in the midst of increasing volumes, changing metrics, and staff burnout, during the annual UNOS Transplant Management Forum (TMF) taking place April 11-13 in Phoenix, Arizona.
Read more on CareDx. com here.

Loading
Posted on

UPDATE — CareDx Wins $44.9M in Damages in False Advertising Trial Against Natera; Natera Intentionally Deceived Transplant Community

Loading

Jury Finds Natera Falsely Advertised its Prospera Kidney Transplant Technology

SOUTH SAN FRANCISCO, Calif., March 23, 2022 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that the Company won its false advertising case against Natera (Nasdaq: NTRA) as a jury found that Natera intentionally and recklessly misled the transplant community by deliberately engaging in false advertising in the promotion and marketing of its Prospera kidney transplant rejection assessment test. CareDx was awarded monetary damages totaling $44.9M: $21.2M in compensatory damages and $23.7M in punitive damages. Read more on CareDx.com.

Loading